CO5150194A1 - Inhibidores hidroxamato inversos de las metalopreteinasas matriciales - Google Patents

Inhibidores hidroxamato inversos de las metalopreteinasas matriciales

Info

Publication number
CO5150194A1
CO5150194A1 CO00003867A CO00003867A CO5150194A1 CO 5150194 A1 CO5150194 A1 CO 5150194A1 CO 00003867 A CO00003867 A CO 00003867A CO 00003867 A CO00003867 A CO 00003867A CO 5150194 A1 CO5150194 A1 CO 5150194A1
Authority
CO
Colombia
Prior art keywords
group
alkyl
hydrogen
heterocycle
independently selected
Prior art date
Application number
CO00003867A
Other languages
English (en)
Inventor
Michael L Curtin
Dai Yujia
Steven K Davidsen
H Robin H Heyman
James H Holms
Michael R Michaelides
Douglas H Steinman
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CO5150194A1 publication Critical patent/CO5150194A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de fórmula (I),<EMI FILE="00003867_1" ID="1" IMF=JPEG >ó una sal ó precursor de droga farmacéuticamente aceptables de éste, en dondeW1 se selecciona del grupo conformado por(1) -O-,(2) -CH2O-, y(3) -CH2-;en donde cada grupo se ilustra de modo que su extremo izquierdo corresponde al extremo que va unido al carbono que contiene R1 y R2, y su extremo derecho el que se une al carbono que contiene R3 y R4;X se selecciona del grupo conformado por(1) -O-,y(2) -N(R7)-, en donde R7 se selecciona del grupo conformado por(a) hidrógeno,(b) alquil,(c) -S02-alquil,y(d) alcanoil;R1 y R2 son independientemente seleccionados del grupo conformado por(1) hidrógeno,(2) alquil,y(3) hidroxialquil;R3 y R4 son independientemente seleccionados del grupo conformado por(1) hidrógeno,y(2) alquil,óR3 y R4 tomados en conjunto son oxo,óR3 y R4, tomados en conjunto con el átomo de carbono al cual van ligados, forman un anillo cicloalquil;R5 y R6 son independientemente seleccionados del grupo conformado por(1) hidrógeno,(2) alquil,(3) perfluoroalquil,- 2 -(4) halo,(5) haloalquil,(6) alcoxi,(7) hidroxi,(8) hidroxialquil,(9) alcoxialquil,y(10) nitro;Y1 se selecciona del grupo conformado por(1) un enlace covalente,(2) -O-,(3) alquileno de dos a cuatro átomos de carbono,(4) piperidinenil,(5) alquenileno de dos átomos de carbono,(6) alquinileno de dos átomos de carbono,(7) -SO2-,y(8) -C(O)-;Ar se selecciona del grupo conformado por(1) fenil,(2) piridil,(3) pirazinil,(4) piridazinil,(5) furil,(6) tienil,(7) isoxazolil,(8) oxazolil,(9) tiazolil,y(10) isotiazolil,en donde (1) - (10) pueden ir opcionalmente sustituidos con uno, dos, ó tres sustituyentes independientemente seleccionados del grupo conformado por(a) alquil,(b) alcoxi, en donde el alcoxi puede ir opcionalmente sustituido con alcoxi,(c) -(alquileno)-C02R8, en donde R8 es hidrógeno ó alquil,(d) -(alquileno)-NR9R10, en donde R9 y R10 son independientemente seleccionados del grupo conformado por(i) alquil,(ii) fenil,y(iii) fenilalquil,en donde para los casos de (ii) y (iii), el fenil y la porción fenil del fenilalquil pueden ir opcionalmente sustituidos con uno ó dos sustituyentes independientemente seleccionados del grupo conformado por halo y alcoxi,(e) alcoxialquil,(f) ciano,(g) cianoalquil,(h) halo,(i) haloalquil,j) hidroxi,(k) hidroxialquil,(I) tioalcoxi,(m) tioalcoxialquil,(n) fenilalcoxi,(o) fenoxi,(p) fenoxialquil,(q) (heterociclo)oxi,(r) (heterociclo)oxialquil,(s) perfluoroalquil,(t) perfluoroalcoxi,(u) sulfinilalquil,(v) sulfonilalquil,<EMI FILE="00003867_2" ID="2" IMF=JPEG >, en donde A se selecciona del grupo conformado por -CH2-, -CH2O- y -O-; y B se selecciona del grupo conformado por -C(O)- y -(C(R")2)v -, en donde R" es ya sea hidrógeno ó alquil, y v toma valores entre 1 - 3,y(x) -N(R8)S02R11, en donde R11 se selecciona del grupo conformado por(i) hidrógeno,(ii) alquil, y(iii) -N(R8)(R11), en donde R12 es hidrógeno ó alquil,en donde para los casos de (q) y (r), la porción heterociclo de (heterociclo)oxi, y la de (heterociclo)oxialquil se seleccionan del grupo conformado por(i) piridil,(ii) pirazinil,(iii) piridazinil,(iv) furil,(v) tienil,(vi) isoxazolil,(vii) oxazolil,(viii) tiazolil,y(ix) isotiazolil,y en donde para los casos de (q) y (r), la porción heterociclo del (heterociclo)oxi y del (heterociclo)oxialquil - 3 -pueden ir opcionalmente sustituidas con uno ó dos sustituyentes independientemente seleccionados del grupo conformado por (i) alquil,(ii) alcoxi,(iii) perfluoroalquil,(iv) halo,(v) ciano,(vi) cianoalquil,(vii) haloalquil,y(viii) alcanoil, yen donde para los casos de (o) y (p), la parte fenil del fenoxi y del fenoxialquil pueden ir opcionalmente sustituidas con uno ó dos sustituyentes independientemente seleccionados del grupo conformado por(i) alquil,(ii) alcoxi,(iii) perfluoroalquil,(iv) halo,(v) ciano,(vi) cianoalquil,(vii) haloalquil,y(viii) alcanoil.
CO00003867A 1999-01-27 2000-01-25 Inhibidores hidroxamato inversos de las metalopreteinasas matriciales CO5150194A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23908799A 1999-01-27 1999-01-27

Publications (1)

Publication Number Publication Date
CO5150194A1 true CO5150194A1 (es) 2002-04-29

Family

ID=22900549

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00003867A CO5150194A1 (es) 1999-01-27 2000-01-25 Inhibidores hidroxamato inversos de las metalopreteinasas matriciales

Country Status (28)

Country Link
US (1) US20020007060A1 (es)
EP (1) EP1147101B1 (es)
JP (1) JP4718686B2 (es)
KR (1) KR100748010B1 (es)
CN (1) CN1222519C (es)
AR (1) AR029329A1 (es)
AT (1) ATE228122T1 (es)
AU (1) AU764383B2 (es)
BG (1) BG105782A (es)
BR (1) BR0007278A (es)
CA (1) CA2358951C (es)
CO (1) CO5150194A1 (es)
CZ (1) CZ20012591A3 (es)
DE (1) DE60000819T2 (es)
DK (1) DK1147101T3 (es)
ES (1) ES2187443T3 (es)
HK (1) HK1043115A1 (es)
HU (1) HUP0105477A2 (es)
IL (1) IL143713A0 (es)
NO (1) NO20013669L (es)
NZ (1) NZ512372A (es)
PL (1) PL349771A1 (es)
PT (1) PT1147101E (es)
SK (1) SK10582001A3 (es)
TR (1) TR200102159T2 (es)
TW (1) TWI225486B (es)
WO (1) WO2000044739A1 (es)
ZA (1) ZA200104979B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU2001298065A1 (en) * 2001-01-12 2003-09-02 Abbott Laboratories Process for the preparation of matrix metalloproteinase inhibitors
WO2003022801A1 (fr) 2001-09-07 2003-03-20 Kaken Pharmaceutical Co., Ltd. Derives d'acide hydroxamique inverse
US7790767B2 (en) * 2005-06-27 2010-09-07 Nabriva Therapeutics Forschungs Gmbh Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2015107139A1 (en) 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0780386T3 (da) * 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer

Also Published As

Publication number Publication date
ATE228122T1 (de) 2002-12-15
TWI225486B (en) 2004-12-21
EP1147101B1 (en) 2002-11-20
CA2358951C (en) 2009-10-20
KR20010101709A (ko) 2001-11-14
WO2000044739A1 (en) 2000-08-03
PL349771A1 (en) 2002-09-09
DE60000819D1 (de) 2003-01-02
HK1043115A1 (zh) 2002-09-06
JP2002535398A (ja) 2002-10-22
JP4718686B2 (ja) 2011-07-06
CZ20012591A3 (cs) 2001-12-12
AR029329A1 (es) 2003-06-25
HUP0105477A2 (hu) 2002-05-29
CN1339032A (zh) 2002-03-06
EP1147101A1 (en) 2001-10-24
NZ512372A (en) 2003-01-31
CA2358951A1 (en) 2000-08-03
PT1147101E (pt) 2003-04-30
DK1147101T3 (da) 2003-03-10
NO20013669D0 (no) 2001-07-26
TR200102159T2 (tr) 2001-12-21
AU764383B2 (en) 2003-08-14
DE60000819T2 (de) 2003-09-04
IL143713A0 (en) 2002-04-21
ZA200104979B (en) 2002-09-18
KR100748010B1 (ko) 2007-08-09
NO20013669L (no) 2001-09-27
ES2187443T3 (es) 2003-06-16
AU2739100A (en) 2000-08-18
US20020007060A1 (en) 2002-01-17
CN1222519C (zh) 2005-10-12
BG105782A (en) 2002-04-30
BR0007278A (pt) 2001-11-27
SK10582001A3 (sk) 2001-12-03

Similar Documents

Publication Publication Date Title
RU2221781C2 (ru) Тиолсульфоновые соединения в качестве ингибитора матриксной металлопротеазы и способы лечения
TWI354666B (en) Heterocyclic aspartyl protease inhibitors
CO5150235A1 (es) Agentes tiromimetricos antiobesidad roaceticos que los contiene
KR950702982A (ko) 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives)
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
RU2011106374A (ru) Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
KR940005633A (ko) 약제학적으로 유용한 항경련제 설파메이트의 이미데이트 유도체
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
KR970702251A (ko) 허혈성 질환에 기인하는 증상의 개선 또는 치료약 및 이에 유용한 화합물(Ameliorant or0 remedy for symptoms caused by ischemic diseases and compounds useful therefor)
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20031012A1 (es) Compuesto inhibidor de la hepatitis c
KR960010000A (ko) 종양괴사인자(tnf)생성 저해제로서의 카테콜 디에테르 화합물
CO5300399A1 (es) Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
CO5231190A1 (es) Combinaciones de compuestos activos del tipo de los cetoenoles ciclicos con piretroides
AR061438A1 (es) Derivados de entacapone
CO5150194A1 (es) Inhibidores hidroxamato inversos de las metalopreteinasas matriciales
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
CA2423007A1 (en) Spiro derivatives and adhesion molecule inhibitors containing the same as effective ingredients
RU2010107603A (ru) Производные n-(2-тиазолил)амида для лечения ожирения, диабетов и сердечно-сосудистых заболеваний
MA29559B1 (fr) Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
CO5261611A1 (es) Nuevos derivados azabibiclooctano utiles en el tratamiento de arritmias cardiacas
ATE155792T1 (de) Ungesatigte 17-beta-substituierte-3-carboxy steroide
ATE343566T1 (de) Propanamine derivate als serotonin und norepinephrin reuptake-inhibitoren
KR910007953A (ko) 6-0-메틸에리트로마이신 a 9-옥심 유도체
RU96123713A (ru) Тиадиазолы и их применение в качестве противопикорнавирусного средства